A practical guide for providers on helping patients find Breyna in stock. Includes availability strategies, alternative inhalers, workflow tips, and patient resources.
You've written the prescription. The patient understands their treatment plan. Everything's on track — until the pharmacy says they don't have Breyna (Budesonide/Formoterol Fumarate Dihydrate) in stock. For patients managing asthma or COPD, this isn't just an inconvenience. It's a gap in care that can lead to exacerbations, ED visits, and lost trust in the treatment plan.
As a prescriber, you're in a unique position to help patients navigate these availability challenges. This guide provides practical steps your practice can take right now.
Breyna, launched in July 2023 as the first FDA-approved generic of Symbicort, is not on the FDA's official drug shortage list as of early 2026. However, localized availability gaps persist across the country. The root causes include:
For a detailed supply timeline, see our provider shortage briefing.
From the patient's perspective, the experience is simple and frustrating: they go to the pharmacy, and Breyna isn't there. But several specific barriers are at play:
Set expectations during the appointment. Let patients know that Breyna may not always be immediately available at every pharmacy, and give them a plan:
This simple conversation can prevent panic and non-adherence when the patient encounters a stock-out.
Give patients (or include on the prescription) the specific NDC numbers for both Breyna strengths. This helps pharmacists locate the exact product from their wholesaler more efficiently. The two formulations are:
Recommend Medfinder to patients as a way to check real-time pharmacy stock. Patients can search for Breyna by name and location, see which nearby pharmacies have it, and avoid wasted trips. Consider adding Medfinder to your patient handouts or after-visit summaries.
Consider writing a backup prescription or noting in the chart that if Breyna is unavailable, the patient may be switched to:
This reduces the chance of a patient going without any ICS/LABA therapy during a stock-out.
Cost barriers can compound availability challenges. Make sure patients know about:
For a patient-friendly breakdown, share our guide to saving money on Breyna.
When you need to switch a patient from Breyna, here's a quick comparison:
Refer to the American Lung Association's comparative dosing chart for equivalent ICS doses across products. For the patient-facing version, see alternatives to Breyna.
Integrating these strategies into your clinical workflow doesn't have to be complicated:
Medication availability challenges are frustrating for everyone — patients, pharmacists, and providers alike. But with proactive communication, backup plans, and the right tools, you can significantly reduce the impact on your patients' respiratory care.
Point your patients to Medfinder for real-time availability, build alternatives into your prescribing workflow, and make sure no patient goes without their maintenance inhaler because of a supply hiccup.
For more on the Breyna supply landscape, read our shortage briefing for providers. For provider-specific cost guidance, see how to help patients save money on Breyna.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
